Stock Performance and Market Context
On 16 Sep 2026, Shree Ganesh Biotech India Ltd’s share price touched Rs.0.47, setting a new 52-week and all-time low. This price point represents a 40.0% decline from its 52-week high of Rs.0.80. The stock’s performance over various time frames starkly contrasts with the broader market, as measured by the Sensex. For instance, the company’s one-year return stands at -39.74%, while the Sensex gained 9.93% over the same period. Year-to-date, the stock has fallen 24.19%, compared to the Sensex’s 12.93% decline.
Shorter-term trends also indicate sustained weakness. The stock declined 2.08% on the day it hit the all-time low, while the Sensex rose 0.27%. Over one month, the stock lost 9.62%, more than double the Sensex’s 4.88% fall. The three-month performance shows an 18.97% drop against the Sensex’s 3.39% decline. Over five years, the stock has plummeted 93.15%, whereas the Sensex has surged 25.47%.
Technical Indicators Confirm Bearish Momentum
Technical analysis underscores the bearish trend. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The overall technical trend is classified as bearish since 16 June 2026, when the price was ₹0.58. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory signal bearish momentum on both weekly and monthly charts. Immediate support is at the current 52-week low of ₹0.47, with resistance levels at ₹0.50 (20-day moving average), ₹0.56 (100-day moving average), and ₹0.59 (200-day moving average).
Financial Metrics Highlight Strained Fundamentals
Shree Ganesh Biotech India Ltd’s financial profile reveals several areas of concern. The company is currently loss-making, with no positive trailing twelve months (TTM) price-to-earnings ratio available. Its price-to-book value stands at a low 0.30x, indicating the market values the company at less than one-third of its book value. Enterprise value to EBITDA and EBIT ratios are negative at -10.87x, reflecting ongoing earnings deficits. The EV to sales ratio is 3.81x, while EV to capital employed is 0.30x.
Dividend metrics are absent, with no dividend yield or payout reported, consistent with the company’s loss-making status. The company’s ability to service debt is weak, with an average EBIT to interest ratio of 0.35x, signalling limited earnings relative to interest obligations. Return on equity (ROE) averages 2.54%, reflecting low profitability relative to shareholders’ funds.
Quarterly Financial Trends Show Flat to Negative Results
Recent quarterly results indicate flat to negative financial performance. The company reported its lowest quarterly PBDIT at Rs. -0.89 crore and PBT less other income also at Rs. -0.89 crore. Earnings per share (EPS) for the quarter stood at a minimal -0.01, marking the lowest level recorded. Negative EBITDA of Rs. -1.76 crore further emphasises the company’s earnings challenges.
Over the past year, profits have declined sharply by 86%, while the stock price has fallen 38.46%. These figures highlight the disconnect between market valuation and financial performance, with the stock trading at risky levels compared to its historical averages.
Quality and Ownership Structure
The company’s overall quality grade is below average, reflecting long-term financial underperformance. Key quality indicators include a 5-year sales decline of 31.22% and a 5-year EBIT contraction of 204.98%. Despite weak profitability and growth metrics, the company maintains a good capital structure with low leverage and no promoter share pledging. Institutional holdings are minimal at 1.42%, with the majority of shares held by non-institutional investors.
Delivery Volumes and Market Activity
Recent delivery volumes show a slight increase, with a 1-day delivery change of 17.67% compared to the 5-day average. The trailing one-month average delivery volume stands at 4.43 lakh shares, marginally higher than the previous month’s 4.34 lakh shares. On 15 Sep 2026, the delivery volume was 5.48 lakh shares, representing 66.65% of total volume, indicating some trading activity despite the stock’s depressed price.
Summary of Market and Financial Position
Shree Ganesh Biotech India Ltd’s stock has reached an unprecedented low, reflecting a prolonged period of financial underperformance and market scepticism. The company’s weak profitability, negative earnings, and subdued growth metrics have contributed to its diminished valuation and bearish technical outlook. While the stock’s micro-cap status and low institutional participation add to its volatility, the absence of dividend payouts and negative EBITDA underline the challenges faced by the company.
Overall, the data portrays a company grappling with significant financial headwinds, as evidenced by its deteriorated market position and subdued investor confidence.
